It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Substantial reduction in losses
Demand normalisation post the second wave contributed to the steady growth
A treatment to prevent extreme symptoms and cut hospitalisation
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company is eligible for 12 months exclusivity from launch
The company has strong product launches both in India and overseas
Subscribe To Our Newsletter & Stay Updated
